ICON plc is a global provider of clinical development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees.
ProSciento is a full scope clinical R&D services provider, exclusively focused on diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all relevant metabolic drug and device classes. Through its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, and operational execution from… Read more
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities… Read More
Antaros Medical is pioneering imaging methodologies to design and deliver clinical imaging studies for improved, evidence-based decision making in drug development. The company is specialized in cardio-metabolic diseases (incl NAFLD/NASH) and oncology. The company has today a global network of collaboration partners and customers, including both big and small drug developing companies, and is a partner in several European collaboration initiatives eg Innovative Medicines Initiative (IMI).
As leaders in clinical trials services, experts from Cardiocore and VirtualScopics are the Research division of BioTelemetry, Inc., one of the world’s largest connected health companies. As BioTel Research, they offer global operational support for cardiovascular monitoring in all therapeutic areas, and advanced imaging services in oncology, cardiovascular, metabolic, musculoskeletal, neurologic and medical device studies
… Read more
DILIsym Services, Inc. (DSS), a Simulations Plus company, improves the safety and efficacy of new therapeutics by utilizing their proprietary DILIsym® and NAFLDsym® software, respectively. These quantitative systems models are used to predict and understand the responses to treatment, including non-alcoholic fatty liver disease (NAFLD). Simulation results are used to optimize clinical trial protocols, inform candidate selection, guide risk-benefit decisions, identify personalized medicine approaches, and support regulatory communications.
HepQuant-SHUNT, -STAT, and -FLOW are sensitive, reproducible, accurate, and minimally-invasive tests of global liver function and physiology. They target not only the liver but also the portal circulation and generate a Disease Severity Index (DSI), which ranges from 0 (healthy) to 50 (severe liver disease). DSI may be used for measuring severity of liver disease, tracking disease progression, and monitoring treatment effects. HepQuant’s services include study design, training, consultation, Test Kits, and Laboratory Analyses.
Aasta Pharmaceuticals, LLC is a start-up company focused on niacin-based therapy for nonalcoholic steatohepatitis (NASH), major complication of nonalcoholic fatty liver disease(NAFLD). It is founded on discoveries that niacin inhibits and reverses hepatic steatosis, inflammation and fibrosis by unique mechanisms of action. This is a novel and innovative patented use of niacin. Aasta seeks partnership with companies interested in combinational therapy to synergistically be superior to either drug alone.
Metabolon, Inc. is the world’s leading health technology company advancing metabolomics in precision medicine and life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives.
Navidea and its therapeutic subsidiary, Macrophage Therapeutic, are developing imaging and therapeutic products that target the CD206 (mannose receptor) found on activated macrophages. Because of extremely high binding (Kd’s of 10-11 to 10-13) of its proprietary delivery agents, Navidea has been able to effectively image both M1 and M2 macrophages in humans. Recently published data confirms M1 targeting, using our FDA approved delivery agent, based on clear imaging of… Read more